VACCINATION WITH THE RUSSIAN INFLUENZA VIROSOME-FORMULATED VACCINE ULTRIX® IN ADULTS 18-60 YEARS OF AGE
This prospective randomized clinical observation of 18-60-year-old adults vaccinated with the Russian influenza split virosome-formulated inactivated vaccine Ultrix® has evaluated its reactogenicity, safety, immunogenicity, and preventive efficacy. The vaccine shows high safety profile, low reactogenicity, sufficient immunogenicity, and high preventive efficacy.